MFS
LCTX icon

Madrona Financial Services’s Lineage Cell Therapeutics LCTX Stock Holding History

Madrona Financial Services’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-15,000
Closed -$13.6K – 119
2024
Q3 		$13.6K Hold
15,000
– – ﹤0.01% 113
2024
Q2 		$15K Hold
15,000
– – ﹤0.01% 100
2024
Q1 		$22.2K Hold
15,000
– – 0.01% 99
2023
Q4 		$16.4K Buy
+15,000
New +$16.4K 0.01% 84

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Madrona Financial Services's LCTX Position: Q4 2024 in Review

Madrona Financial Services sold out of Lineage Cell Therapeutics (LCTX) in Q4 2024, closing a stake of 15,000 shares — an estimated $13.6K sold.

Madrona Financial Services first reported a position in LCTX in Q4 2023 and held it in 4 quarters. The position peaked at $22.2K in Q1 2024. 126 funds tracked by Wall St. Rank hold LCTX as of Q4 2024.

  • Madrona Financial Services reported no remaining Lineage Cell Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Madrona Financial Services sold 15,000 Lineage Cell Therapeutics shares in Q4 2024, an estimated $13.6K.
  • Madrona Financial Services first reported a position in Lineage Cell Therapeutics in Q4 2023 and held it in 4 quarters.
  • Madrona Financial Services's Lineage Cell Therapeutics position peaked at $22.2K in Q1 2024.
  • 126 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2024.

Based on Madrona Financial Services's 13F filing for Q4 2024, filed 17 Jan 2025.